Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, announced today that it has closed a non-brokered private placement of unsecured convertible debentures, raising aggregate gross proceeds of C$3,673,000. The company issued 3,673 Convertible Debentures, each with a principal amount of C$1,000, to investors.
The debentures carry a 25% annual simple interest rate and mature 14 months from the closing date. If not repaid by the Maturity Date, holders may convert the outstanding principal into common shares at a price of C$1.42 per share, which represents the market price at the reservation date less a 20% discount permitted by TSX policies. Accrued but unpaid interest may also be converted at the greater of the Conversion Price or the volume-weighted average trading price over the five preceding trading days, less the permitted discount.
The proceeds from the Offering are expected to be used for general working capital and to advance the company's drug development programs, including its lead candidate L-DOS47, a Tumor Defense Breaker antibody-enzyme conjugate designed to target CEACAM6-expressing tumors. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and forms the foundation for next-generation bispecific antibody-drug conjugates in discovery. Helix also progresses two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to IV administration.
The financing structure with a 25% interest rate and potential conversion at a discount reflects the high-risk nature of clinical-stage biotechnology investments. For business leaders, this news highlights the capital-intensive path of oncology drug development and the reliance on convertible debt as a funding mechanism. The terms may dilute existing shareholders if conversion occurs, but also provide Helix with non-dilutive capital in the near term. The company's focus on hard-to-treat cancers and its pipeline of novel therapies could offer significant upside if clinical trials succeed, but investors should weigh the risks inherent in early-stage drug development.
The Convertible Debentures and any shares issuable are subject to a statutory four-month hold period. No finder's fees were paid. For more information, visit Helix BioPharma's website.
